Russell Investments Group, Ltd. Beyond Spring Inc. Transaction History

Russell Investments Group, Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 05, 2022	SELL	$1.68 - $5.01 $3,763 - $11,222	-2,240 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$9.26 - $31.31 $137,974 - $466,519	-14,900 Reduced 86.93%	2,240 $35,000
Q2 2021 Aug 04, 2021	SELL	$9.37 - $12.12 $15,170 - $19,622	-1,619 Reduced 8.63%	17,140 $178,000
Q1 2021 May 10, 2021	SELL	$10.61 - $15.77 $247,552 - $367,945	-23,332 Reduced 55.43%	18,759 $207,000
Q4 2020 Feb 08, 2021	BUY	$10.21 - $17.31 $18,612 - $31,556	1,823 Added 4.53%	42,091 $512,000
Q3 2020 Nov 09, 2020	SELL	$9.99 - $16.13 $122,017 - $197,011	-12,214 Reduced 23.27%	40,268 $535,000
Q2 2020 Aug 05, 2020	BUY	$11.21 - $18.15 $174,988 - $283,321	15,610 Added 42.34%	52,482 $788,000
Q1 2020 May 06, 2020	BUY	$9.68 - $18.47 $356,920 - $681,025	36,872 New	36,872 $471,000
Q4 2019 Jan 29, 2020	SELL	$11.83 - $18.68 $443,755 - $700,705	-37,511 Closed	0 $0
Q3 2019 Nov 01, 2019	BUY	$15.33 - $23.85 $575,043 - $894,637	37,511 New	37,511 $678,000

5.55M

26K

2.4K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $63.1M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.